Express News | Argus Research: Raised Eli Lilly's target price from $770 to $840, maintaining a “buy” rating.

Breakings14:27

Lilly Settles with Spa Selling Counterfeit Mounjaro and Zepbound Products

GLONGHUI, May 15 | Eli Lilly said it has reached a settlement agreement with a medical spa agency that sold products counterfeit its popular diabetes drug Mounjaro and weight loss treatment Zepbound. As part of the agreement, Totality Medispa will make a payment to Eli Lilly and will no longer use the Eli Lilly brand to promote any of its products. Earlier, Eli Lilly and Novo Nordisk sued several medical spas and compound pharmacies to stop selling products claiming to contain active ingredients from commonly used diet pills from these two pharmaceutical companies. Eli Lilly in a statement

Gelonghui Finance11:15

Qiaoshui's Q1 favors technology stocks! Newly opened warehouses with Amazon and AMD, Pinduoduo and P&G have continuously reduced their holdings

Amazon was Qiaoshui's largest newly opened stock in the first quarter. After almost clearing its inventory last year, Apple's holdings were greatly increased again, and Pinduoduo and P&G's holdings were reduced for several consecutive quarters.

wallstreetcn08:23

Eli Lilly Provides Update On Mounjaro And Zepbound Compounding Litigation; Enters Settlement Requiring Totality Medispa To Make Monetary Payment, Prohibiting Misleading Conduct, And Reporting Adverse Events To FDA

Eli Lilly Provides Update On Mounjaro And Zepbound Compounding Litigation; Enters Settlement Requiring Totality Medispa To Make Monetary Payment, Prohibiting Misleading Conduct, And Reporting Adverse

Benzinga05:15

Lilly Settles With Spa Selling Mounjaro, Zepbound Knock-Offs -- WSJ

Eli Lilly has reached its first legal settlement with one of the spas that it had accused in lawsuits of infringing its trademarks by selling alternative versions of Lillys hot-selling drugs for diabetes and weight loss.

WSJ04:22

New Analyst Adjustments Prove Little Help to Eli Lilly (NYSE:LLY)

TipRanks01:30